Long‐term efficacy and toxicity of bevacizumab‐based therapy in children with recurrent low‐grade gliomas

摘要: Background Because definitive resection or radiotherapy for pediatric low-grade gliomas (LGGs) may be associated with severe and permanent adverse effects, medical management has taken a significant role. Bevacizumab-based therapy demonstrated encouraging responses; however, longer-term toxicity, response durability alternative dosing regimens have not been evaluated. Procedure This was retrospective review of children multiply recurrent, progressive LGGs treated bevacizumab-based followed at least 12 months after treatment completion. Toxicity uniformly graded imaging centrally reviewed. Results All fourteen patients had failed two prior regimens; six dissemination. Patients received initial median age 5.3 years (range, 1–12 years). Median duration 1–24 months). an objective response; 2 stable disease. time to maximum 9 weeks 7–17 weeks). No progressed on therapy, although 13/14 stopping bevacizumab 5 months. Four were re-treated all again responded stabilized. Alternative strategies effective, including monotherapy prolonging the interval 3 weeks. High-grade bevacizumab-related toxicities consisted grade proteinuria (n = 2), primary inflammatory arthritis (n = 1), somnolence (n = 1). Toxicities resolved within 6 cessation except one case hypertension. Conclusions Bevacizumab-based is successful inducing rapid LGG response. progressing off-therapy successfully bevacizumab. Nearly tumors progress once discontinued. are insignificant but usually reversible. Pediatr Blood Cancer 2013; 60: 776–782. © 2012 Wiley Periodicals, Inc.